

## Evoked Pharma (EVOK - \$ 4.27)

### 4Q15: All Eyes Are On METO IN-003 Trial Results That Are Likely To Come in a Few Months

Yesterday after the market closed, EVOK reported 4Q15 financial results with a net loss of (\$2.6MM), slightly better than the estimates of Laidlaw (\$3.0MM) and the Street (\$3.1MM). Net loss per share was (\$0.37) vs. (\$0.46) and (\$0.45) for Laidlaw and the Street, respectively. EVOK ended 2015 with ~\$8.7MM cash, sufficient for operations into early 4Q16, in our opinion.

- METO IN-003 study update.** During the conference call, EVOK reiterated that patient enrollment should be completed in the near future given their recent reported 93% (186/200) enrollment completion (see our 2016-03-01 EVOK note). Since the treatment duration is 4 weeks, we estimate that the top-line data could potentially be available in mid-2016 to 3Q16 (somewhat less than a quarter after completion of patient enrollment, in our estimate). If the data are positive, EVOK would conduct a pre-NDA meeting prior to a 505(b)(2) filing, potentially by year end 2016 in our estimate. Further, although it would be too late to report the Phase III results, if positive, at the upcoming Digestive Disease Week (DDW) conference (May 21–24), EVOK still has several opportunities potentially to present the top-line data at one of the American Gastroenterological Association (AGA) medical meetings in 2H16 to increase the awareness about EVK-001 among gastroenterologists. At the DDW meeting, EVOK will instead report positive results of the thorough electrocardiogram (ECG) study as EVK-001 did not prolong the cardiac QT and corrected QT (QTc) intervals in healthy subjects across a range of plasma concentrations. The results of the thorough QT/QTc study would be included as part of an approval application of EVK-001. Given EVK-001 is one of the clinically most advanced treatments in development in the gastroparesis space, should the drug get approved and marketed, EVOK could potentially afford some first mover advantage in the market place, in our opinion.
- Action.** We reiterate our Buy rating and \$19 target price based on our peer comparable, cash driven NPV and forward price/sales analyses. Our recommendation is based on potential success of the METO IN-003 study and the positive commercial outlook of EVK-001 in gastroparesis treatment.

*Healthcare/Biotechnology*

Ticker: **EVOK**  
Rating: **Buy**  
Price Target: **\$ 19.00**

#### Trading Data:

Last Price (03/10/2016)	\$ 4.27
52-Week High (4/14/2015)	\$ 8.00
52-Week Low (1/20/2016)	\$ 2.37
Market Cap. (MM)	\$ 31
Shares Out. (MM)	7

#### Earnings Estimates: (per share)

(Dec)	1Q	2Q	3Q	4Q	FY	P/E
<b>FY-16E</b>	-0.39	-0.41	-0.18	-0.14	-1.04	NM
<b>FY-15A</b>	-0.58	-0.52	-0.42	-0.37	-1.87	NM
<b>FY-14A</b>	-0.49	-0.59	-0.63	-0.48	-2.20	NM
<b>FY-13A</b>	-0.44	-0.21	-0.40	-0.27	-1.20	NM

#### Yale Jen, Ph.D.

Managing Director/Senior  
Biotechnology Analyst  
(212) 953-4978  
yjen@laidlawltd.com

Source: Laidlaw & Company estimates

FOR ANALYST CERTIFICATION AND DISCLOSURES, PLEASE SEE DISCLOSURES SECTION AT THE END OF THIS REPORT. This report has been prepared by Laidlaw & Co (UK), Ltd. Investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. All prices are those current at the end of the previous trading session unless otherwise indicated. Prices and consensus estimates are sourced from a reliable market source

**Table 1: Estimated and reported 4Q15 results**

<b>4Q15 Estimates and Reported Results</b>			
<b>(\$,000)</b>	<b>Laidlaw Estimate</b>	<b>Actual</b>	<b>Consensus</b>
<b>Total revenue</b>	<b>\$0.0</b>	<b>\$0.0</b>	<b>\$0.0</b>
<b>Total op. profit (loss)</b>	<b>(\$2,911)</b>	<b>(\$2,551)</b>	<b>(\$3,100)</b>
R&D	\$2,058	\$1,708	
SG&A	\$852	\$843	
<b>EPS</b>	<b>(\$0.46)</b>	<b>(\$0.37)</b>	<b>(\$0.45)</b>
Net income (loss)	(\$2,987)	(\$2,624)	(\$3,100)

Source: Bloomberg, SEC filings and Laidlaw and Co.

### Anticipated Milestones in 2016 and Beyond

Product	Indication	Event	Timing	Importance
EVK-100	Diabetic gastroparesis	Potentially report top-line METO IN-003 Phase III trial results	Mid-3Q16	*****
		Potentially filing via 505(b)(2) pathway for approval	late 2H16	***
		Potential approval	2H17	*****

\*\*\*\* / \*\*\*\*\* Major catalyst event that could impact share price very significantly while \*\*\* event is more informative

Source: Laidlaw & Company and company presentation

## Major Risks

---

**Failures of upcoming clinical studies** Although EVK-001 has demonstrated promising efficacy and a satisfactory safety profile from prior Phase II studies in diabetic gastroparesis; there is no assurance that the upcoming Phase III clinical study can demonstrate efficacy and safety profiles satisfactory enough for gaining clinical approval. Given the clinical study successes are the biggest near-term hurdle to be overcome before EVK-001 can be advanced into commercialization, clinical study failure could significantly impair the value of the company's assets and shareholder value. Overall, we view clinical risks of EVK-001 are more modest relative to Phase III studies of other biotech companies.

**EVK-001 may not reach anticipated sales.** Assuming EVK-001 receives approval and is commercialized, the sales potential could fall short of our forecasts. It is difficult to project accurately the sales potential of EVK-001 in gastroparesis given that the market is relatively mature and is dominated by generic products. The assumption is that EVK-001 could afford more effective drug availability and bypass the hurdle of slow gastric emptying and vomiting. However, the actual clinical performance from the Phase III study could influence physician acceptance for the drug as well as the company's flexibility to price the drug. The lack of a large size comparative clinical study for EVK-001 vs. oral metoclopramide with a superior outcome could also slow down the initial market penetration.

**Lack of diversified product portfolio increases risk if EVK-100 fails.** Since Evoke only has only one product in development and without other prospects on their pipeline, EVOK has very limited options to hedge its risk of product failure. As such, any mishap or failure of EVK-001 development could significantly reduce the value of EVOK shareholders.

**Additional financing could dilute shareholder value.** Regardless of whether or not the company forges additional collaborations with partners to generate non-dilutive revenue to support operations, it is likely that Evoke may need to raise additional cash from investors to fund its operations, especially if the company needs to commercialize EVK-001 by themselves. As such, the share value for existing investors could be diluted. Further, if the company cannot raise equity capital at favorable terms, the share value of current shareholders could be further impaired.

**Limited trading liquidity limits shareholder options.** Daily trading volume and name recognition of EVOK shares are relatively modest. Some investors may be hesitant to own the shares due to illiquid trading volume. This could impose constraints if they want to increase or reduce their positions in a volatile stock market.

Figure 1: Income Statement

Evoke Pharma – Income Statement															
(\$'000)	2014	1Q15	2Q15	3Q15	4Q15	2015	1Q16E	2Q16E	3Q16E	4Q16E	2016E	2017E	2018E	2019E	2020E
<b>Revenue</b>															
EVK-001 sales						0					0	21,354	55,533	94,545	148,265
Product royalty revenue	0	-	-	-	-	0	-	-	-	-	0	0	0	0	0
Total revenue	0	-	-	-	-	0	-	-	-	-	0	21,354	55,533	94,545	148,265
<b>Costs of goods</b>						0					0	1,922	4,998	8,509	13,344
Research and development	9,992	2,420	2,188	1,838	1,708	8,154	1,913	2,143	986	591	5,633	1,183	1,124	1,158	1,192
General and administrative	3,158	1,025	976	820	843	3,664	809	777	746	775	3,107	3,386	3,691	4,023	4,345
Marketing and sales					0	0					0	22,000	23,100	24,486	25,710
<b>Total Operating Expenses</b>	13,150	3,445	3,165	2,657	2,551	11,818	2,722	2,920	1,731	1,367	8,740	28,491	32,913	38,176	44,592
Operating Incomes (losses)	(13,150)	(3,445)	(3,165)	(2,657)	(2,551)	(11,818)	(2,722)	(2,920)	(1,731)	(1,367)	(8,740)	(7,138)	22,620	56,369	103,674
Interest income	10	2	1	1	1	5	1	1	1	1	5	5	5	6	7
Interest expense	(108)	(77)	(78)	(78)	(74)	(307)	(74)	(74)	(74)	(74)	(297)	(326)	(359)	(395)	(395)
Change in fair value of warrant liability	0	0	0	0	0	0	0	0	0	0	0	0	24	(27)	(27)
Total Other Income, net	(98)	(76)	(77)	(77)	(73)	(302)	(73)	(73)	(73)	(73)	(292)	(322)	(330)	(416)	(415)
<b>Income before tax</b>	(13,248)	(3,521)	(3,241)	(2,734)	(2,624)	(12,120)	(2,795)	(2,993)	(1,804)	(1,440)	(9,033)	(7,459)	22,290	55,953	103,258
Tax Rate													32%	32%	32%
Tax	0	0	0	0	0	0	0	0	0	0	0	0	(7,133)	(17,905)	(33,043)
<b>Net Income (Loss)</b>	(13,248)	(3,521)	(3,241)	(2,734)	(2,624)	(12,120)	(2,795)	(2,993)	(1,804)	(1,440)	(9,033)	(7,459)	15,157	38,048	70,216
Net Income (Loss) Applicable to Common Shareholders	(13,248)	(3,521)	(3,241)	(2,734)	(2,624)	(12,120)	(2,795)	(2,993)	(1,804)	(1,440)	(9,033)	(7,459)	15,157	38,048	70,216
Net Earnings (Losses) Per Share—Basic and Diluted	(\$2.20)	(\$0.58)	(\$0.52)	(\$0.42)	(\$0.37)	(\$1.87)	(\$0.39)	(\$0.41)	(\$0.18)	(\$0.14)	(\$1.04)	(\$0.64)	\$1.19	\$2.77	\$4.77
Shares outstanding—basic and diluted	6,032	6,104	6,213	6,495	7,123	6,486	7,173	7,223	10,223	10,273	8,723	11,723	12,723	13,723	14,723
	6,032	6,104	6,213	6,495	7,123	6,486	7,173	7,223	10,223	10,273	8,723	11,723	12,723	13,723	14,723
<b>Margin Analysis (% of Sales/Revenue)</b>															
Costs of goods												9%	9%	9%	9%
R&D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1%
MG&A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	20%
Operating Income (loss)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	70%
Net Income	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	47%
<b>Financial Indicator Growth Analysis (YoY%)</b>															
Total Revenue	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	57%
R&D	944%	153%	-24%	-40%	-22%	-18%	-81%	-2%	-46%	-65%	-31%	-79%	-5%	3%	3%
SG&A	92%	-38%	58%	12%	14%	16%	-74%	-20%	-9%	-8%	-15%	9%	9%	9%	8%
Marketing and sales						NA					NA	200%	5%	6%	5%
Operating Loss	405%	32%	-9%	-30%	-12%	-10%	-79%	-8%	-35%	-46%	-26%	-18%	-417%	149%	84%
Total Other Income, net	-58%	-68%	39%	1732%	1252%	209%	-25%	-5%	-5%	0%	-3%	10%	3%	26%	0%
Pretax Income	367%	24%	-9%	-29%	-10%	-9%	-79%	-8%	-34%	-45%	-25%	-17%	-399%	151%	85%
Net Income	367%	24%	-9%	-29%	-10%	-9%	-79%	-8%	-34%	-45%	-25%	-17%	-303%	151%	85%
EPS	83%	-52%	-11%	-33%	-23%	-15%	-82%	-21%	-58%	-62%	-45%	-39%	-287%	133%	72%

Yale Jen, Ph.D. 212-953-4978

Source: Bloomberg LP; Company reports; Laidlaw & Company estimates.

## DISCLOSURES:

### ANALYST CERTIFICATION

The analyst responsible for the content of this report hereby certifies that the views expressed regarding the company or companies and their securities accurately represent his personal views and that no direct or indirect compensation is to be received by the analyst for any specific recommendation or views contained in this report. Neither the author of this report nor any member of his immediate family or household maintains a position in the securities mentioned in this report.

### EQUITY DISCLOSURES


For the purpose of ratings distributions, regulatory rules require the firm to assign ratings to one of three rating categories (i.e. Strong Buy/Buy-Overweight, Hold, or Underweight/Sell) regardless of a firm's own rating categories. Although the firm's ratings of Buy/Overweight, Hold, or Underweight/Sell most closely correspond to Buy, Hold and Sell, respectively, the meanings are not the same because our ratings are determined on a relative basis against the analyst sector universe of stocks. An analyst's coverage sector is comprised of companies that are engaged in similar business or share similar operating characteristics as the subject company. The analysis sector universe is a sub-sector to the analyst's coverage sector, and is compiled to assist the analyst in determining relative valuations of subject companies. The composition of an analyst's sector universe is subject to change over time as various factors, including changing market conditions occur. Accordingly, the rating assigned to a particular stock represents solely the analyst's view of how that stock will perform over the next 12-months relative to the analyst's sector universe.

*Additional information available upon request.*

# Laidlaw & Co (UK) Ltd. has not provided any investment banking services for the company (ies) mentioned in this report over the last 12 months.

### RATINGS INFORMATION

#### Rating and Price Target Change History



#### 3 Year Rating Change History

Date	Rating	Closing Price (\$)
04/22/2014	Buy (B)	9.29

#### 3 Year Price Change History

Date	Target Price (\$)	Closing Price, (\$)
04/22/2014	19.00	9.29

Source: Laidlaw & Company

Created by: Blue-Compass.net

Laidlaw & Company Rating System*		% of Companies Under Coverage With This Rating	% of Companies for which Laidlaw & Company has performed services for in the last 12 months	
			Investment Banking	Brokerage
<b>Strong Buy (SB)</b>	Expected to significantly outperform the sector over 12 months.	0.00%	0.00%	0.00%
<b>Buy (B)</b>	Expected to outperform the sector average over 12 months.	65.71%	25.71%	2.86%
<b>Hold (H)</b>	Expected returns to be in line with the sector average over 12 months.	0.00%	0.00%	0.00%
<b>Sell (S)</b>	Returns expected to significantly underperform the sector average over 12 months.	0.00%	0.00%	0.00%

### ADDITIONAL COMPANIES MENTIONED

### ADDITIONAL DISCLOSURES

As of the date of this report, neither the author of this report nor any member of his immediate family or household maintains an ownership position in the securities of the company (ies) mentioned in this report.

This report does not provide individually tailored investment advice and has been prepared without regard to the individual financial circumstances and objectives of persons who receive it. Laidlaw & Co (UK), Ltd. recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. The securities, instruments, or strategies discussed in this report may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. This report is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy.

Associated persons of Laidlaw & Co (UK), Ltd not involved in the preparation of this report may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned herein and may trade them in ways different from those discussed in this report. While Laidlaw & Co (UK), Ltd., prohibits analysts from receiving any compensation. Bonus or incentive based on specific recommendations for, or view of, a particular company, investors should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

With the exception of information regarding Laidlaw & Co (UK), Ltd. this report is based on public information. Laidlaw & Co (UK), Ltd makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete and it should not be relied upon as such. Any opinions expressed are subject to change and Laidlaw & Co (UK), Ltd disclaims any obligation to advise you of changes in opinions or information or any discontinuation of coverage of a subject company. Facts and views presented in this report have not been reviewed by, and may not reflect information known to, professionals in other Laidlaw & Co (UK), Ltd business areas. Laidlaw & Co (UK), Ltd associated persons conduct site visits from time to time but are prohibited from accepting payment or reimbursement by the company of travel expenses for such visits. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.

Any trademarks and service marks contained in this report are the property of their respective owners. Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages of any kind relating to such data. This report or any portion thereof may not be reprinted, sold or redistributed without the written consent of Laidlaw & Co (UK), Ltd. This report is disseminated and available primarily electronically, and, in some cases, in printed form.

The information and opinions in this report were prepared by Laidlaw & Co (UK), Ltd. For important disclosures, please see Laidlaw & Co (UK), Ltd.'s disclosure website at [www.Laidlawltd.com](http://www.Laidlawltd.com), or contact your investment representative or Laidlaw & Co (UK), Ltd at 546 Fifth Ave, 5th Floor, New York, NY 10036 USA.

© 2016 Laidlaw & Co. (UK), Ltd.

**NOTES:**